| Literature DB >> 32656269 |
Teshager Dubie1, Yasin Mohammed2.
Abstract
Cutaneous leishmaniasis (CL) is a major public health problem worldwide and spreads to human via the bite of sand flies during blood meal. Following its inoculation, the promastigotes are immediately taken up by phagocytic cells and these leishmania-infected host cells produce proinflammatory cytokines that activate other immune cells and these infected host cells produce more cytokines and reactive nitrogen and oxygen species for efficient control of leishmania infection. Many experimental studies showed that resistance to infection with leishmania paraites is associated with the production of proinflammatory cytokines and activation of CD4+ Th1 response. On the other hand, vulnerability to this parasitic infection is correlated to production of T helper 2 cytokines that facilitate persistence of parasites and disease progression. In addition, some studies have also indicated that CD8+ T cells play a vital role in immune defense through cytokine production and their cytotoxic activity and excessive production of proinflammatory mediators promote amplified recruitment of cells. This could be correlated with excessive inflammatory reaction and ultimately resulted in tissue destruction and development of immunopathogenesis. Thus, there are contradictions regarding the role of immune responses in protection and immunopathogenesis of CL disease. Therefore, the aim of this paper was to review the role of host immune response in protection and its contribution to disease severity for CL infection. In order to obtain more meaningful data regarding the nature of immune response to leishmania, further in-depth studies focused on immune modulation should be conducted to develop better therapeutic strategies.Entities:
Mesh:
Year: 2020 PMID: 32656269 PMCID: PMC7320295 DOI: 10.1155/2020/2496713
Source DB: PubMed Journal: J Immunol Res ISSN: 2314-7156 Impact factor: 4.818
Leishmania species, the disease form they can cause, their geographical distribution, and vectors are summarized.
| Leishmania species | Clinical form in humans | Geographical distribution | Vectors |
|---|---|---|---|
|
| Localized cutaneous leishmaniasis | Ethiopia, Kenya |
|
|
| Localized cutaneous leishmaniasis | North Africa, Middle East, Sub-Saharan Africa, and Sahel belt, Sudan, Pakistan |
|
| L. mexicana∗ | Localized cutaneous leishmaniasis | Central America |
|
|
| Localized cutaneous leishmaniasis | South America, north of the Amazon |
|
|
| Localized cutaneous leishmaniasis | South America, Central America, and Mexico |
|
|
| Localized cutaneous leishmaniasis | West Andes of Peru, Argentine highlands |
|
|
| Visceral leishmaniasis | Middle East and Central Asia to Pakistan, China, Central and South America, Southern Europe, northwest Africa |
|
|
| Visceral leishmaniasis | Ethiopia, Sudan, Kenya, India, China, Bangladesh |
|
@Old World species. ∗New World species.
Figure 1Dendritic cells and macrophages regulate the outcome of Leishmania infection (source: Liu and Uzonna, 2012).
Figure 2The role of neutrophils in leishmania infection control and persistence of infection (adopted from: http://www.nature.com/nri; Phillip Scott and Fernanda O. Novais, 2016).
Figure 3CD4+ Th1vTh2 cell response towards Leishmania infection (source: https://www.google.com; J. H. Ruiz & I. Becker (2007): CD8 cytotoxic T cells in cutaneous leishmaniasis).
Figure 4Cytokine profile in cutaneous leishmaniasis infection (Source: Pathogens and Global Health; Maspi et al.).